Treprostinil

Treprostinil is a prostacyclin mimetic. This page records what three US labels from one sponsor say, one for each route. The label for Remodulin, an injection formulated for subcutaneous or intravenous administration, lists pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise and, separately, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration. The label for Tyvaso, a sterile solution for oral inhalation, lists PAH to improve exercise ability and, separately, pulmonary hypertension associated with interstitial lung disease (WHO Group 3) to improve exercise ability. The label for Orenitram, extended-release tablets, lists PAH to delay disease progression and to improve exercise capacity. Each statement belongs to its own label and route.

Also called Remodulin · TYVASO · Orenitram · Treprostinil sodium · Treprostinil diolamine

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 343048; UNII RUM6K67ESG. MeSH has no descriptor for treprostinil (name lookups on 2026-11-18 found only supplementary concept terms), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class spelled Prostacycline Vasodilator, so the record is filed under the prostacyclin pathway page. The labels read, all by United Therapeutics Corporation, are Remodulin (NDA021272, effective 2026-07-02 in openFDA), Tyvaso (NDA022387, effective 2026-04-14) and Orenitram (NDA203496, effective 2024-11-20). Other treprostinil products and labels, including other inhaled products, were not read. Drugs@FDA lists the ingredient strings treprostinil, treprostinil sodium and treprostinil diolamine; the two salt names are kept as aliases. The statements sit in separate claims and contexts, and none gives a dose or an instruction.

About this drug

Level
Substance
Mechanism
The Remodulin label says the major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.

Claims and evidence

Context Patients with pulmonary arterial hypertension who require transition from epoprostenol, as described in the US label of Remodulin

Recipient
Recipient not specified
Population
Patients who require transition from epoprostenol, as the label states. The passage read gives no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the passage read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients who require transition from epoprostenol, as the label states. The passage read gives no age range.
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The same US label of Remodulin separately lists, for patients who require transition from epoprostenol, reducing the rate of clinical deterioration.

    Applies to Recipient not specified Patients with pulmonary arterial hypertension who require transition from epoprostenol, as described in the US label of Remodulin

    Certainty method
    Not assessed
    Limitations
    This claim is tied to the Remodulin injection label only, and to the transition use the label names. It does not say how a transition is done, and no instruction is recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Background openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA021272.
      Retrieved
      Source effective date
      2026-07-02
      Source state
      Current
      Version fingerprint
      8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260702.
      Retrieved
      Source effective date
      2026-07-02
      Source state
      Current
      Version fingerprint
      8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (Q-K30-TRE-RE-05).
      Retrieved
      Source effective date
      2026-07-02
      Source state
      Current
      Version fingerprint
      8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients with pulmonary arterial hypertension, as described in the US label of Orenitram

Recipient
Recipient not specified
Population
Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the label states. The passage read gives no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the passage read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients with pulmonary arterial hypertension (PAH) (WHO Group 1), as the label states. The passage read gives no age range.
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Orenitram (treprostinil extended-release tablets, United Therapeutics Corporation, application NDA203496; the version dated 2024-11-20 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.

    Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Orenitram

    Certainty method
    Not assessed
    Limitations
    This claim is tied to the Orenitram tablet label only. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Background openFDA drug label record for Orenitram (treprostinil extended-release tablets), United Therapeutics Corporation label: indications and dosage forms

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8ed2003a-c801-411e-831e-d06079bb0d7c (manufacturer United Therapeutics Corporation, application NDA203496), returned on 2026-11-18. The label text is dated 2024-11-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA203496.
      Retrieved
      Source effective date
      2024-11-20
      Source state
      Current
      Version fingerprint
      d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Orenitram (treprostinil extended-release tablets), United Therapeutics Corporation label: indications and dosage forms

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8ed2003a-c801-411e-831e-d06079bb0d7c (manufacturer United Therapeutics Corporation, application NDA203496), returned on 2026-11-18. The label text is dated 2024-11-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20241120.
      Retrieved
      Source effective date
      2024-11-20
      Source state
      Current
      Version fingerprint
      d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for Orenitram (treprostinil extended-release tablets), United Therapeutics Corporation label: indications and dosage forms

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8ed2003a-c801-411e-831e-d06079bb0d7c (manufacturer United Therapeutics Corporation, application NDA203496), returned on 2026-11-18. The label text is dated 2024-11-20 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (Q-K30-TRE-OR-03, Q-K30-TRE-OR-04, Q-K30-TRE-OR-05).
      Retrieved
      Source effective date
      2024-11-20
      Source state
      Current
      Version fingerprint
      d8a098270f8df7a60f3ab00c587921a8e61696526f26db8b624881165be822b0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients with pulmonary arterial hypertension, as described in the US label of Remodulin

Recipient
Recipient not specified
Population
Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the passage read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Remodulin (treprostinil injection, United Therapeutics Corporation, application NDA021272; the version dated 2026-07-02 in openFDA) calls the medicine a prostacyclin mimetic, formulated for subcutaneous or intravenous administration. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise.

    Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Remodulin

    Certainty method
    Not assessed
    Limitations
    This claim is tied to the Remodulin injection label only. The inhaled and oral treprostinil products have their own labels and claims. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a transition use, which sits in a separate claim.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Background openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA021272.
      Retrieved
      Source effective date
      2026-07-02
      Source state
      Current
      Version fingerprint
      8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260702.
      Retrieved
      Source effective date
      2026-07-02
      Source state
      Current
      Version fingerprint
      8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for Remodulin (treprostinil injection with sterile diluent), United Therapeutics Corporation label: indication wording and mechanism (class page)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 6c80bb38-e8db-4138-9f0d-dbbf9c673185 (manufacturer United Therapeutics Corporation, application NDA021272), returned on 2026-11-18. The label text is dated 2026-07-02 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (Q-K30-TRE-RE-03, Q-K30-TRE-RE-04, Q-K30-TRE-RE-06).
      Retrieved
      Source effective date
      2026-07-02
      Source state
      Current
      Version fingerprint
      8850d392fb95b8f7f44f21e4c757f2bdc42fff7625a3783c2bb757648e1280f0
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients with pulmonary arterial hypertension, as described in the US label of Tyvaso

Recipient
Recipient not specified
Population
Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the passage read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients with pulmonary arterial hypertension (PAH; WHO Group 1), as the label states. The passage read gives no age range.
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Tyvaso (treprostinil, a sterile solution for oral inhalation, United Therapeutics Corporation, application NDA022387; the version dated 2026-04-14 in openFDA) calls the medicine a prostacyclin mimetic. It lists treating pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.

    Applies to Recipient not specified Patients with pulmonary arterial hypertension, as described in the US label of Tyvaso

    Certainty method
    Not assessed
    Limitations
    This claim is tied to the Tyvaso inhalation solution label only. Other inhaled treprostinil products have their own labels and were not read. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists pulmonary hypertension with interstitial lung disease, which sits in a separate claim.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Background openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA022387.
      Retrieved
      Source effective date
      2026-04-14
      Source state
      Current
      Version fingerprint
      3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260414.
      Retrieved
      Source effective date
      2026-04-14
      Source state
      Current
      Version fingerprint
      3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (Q-K30-TRE-TY-03, Q-K30-TRE-TY-04, Q-K30-TRE-TY-06).
      Retrieved
      Source effective date
      2026-04-14
      Source state
      Current
      Version fingerprint
      3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients with pulmonary hypertension associated with interstitial lung disease, as described in the US label of Tyvaso

Recipient
Recipient not specified
Population
Patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), as the label states. The passage read gives no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the passage read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), as the label states. The passage read gives no age range.
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The same US label of Tyvaso separately lists treating pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

    Applies to Recipient not specified Patients with pulmonary hypertension associated with interstitial lung disease, as described in the US label of Tyvaso

    Certainty method
    Not assessed
    Limitations
    This claim is tied to the Tyvaso inhalation solution label only, and concerns a different group of pulmonary hypertension from pulmonary arterial hypertension. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Background openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA022387.
      Retrieved
      Source effective date
      2026-04-14
      Source state
      Current
      Version fingerprint
      3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260414.
      Retrieved
      Source effective date
      2026-04-14
      Source state
      Current
      Version fingerprint
      3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for Tyvaso (treprostinil sterile solution for oral inhalation), United Therapeutics Corporation label: indications and mechanism

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id cbc31ab1-a80f-4b50-a3b1-39910b0fb609 (manufacturer United Therapeutics Corporation, application NDA022387), returned on 2026-11-18. The label text is dated 2026-04-14 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (Q-K30-TRE-TY-03, Q-K30-TRE-TY-05, Q-K30-TRE-TY-06).
      Retrieved
      Source effective date
      2026-04-14
      Source state
      Current
      Version fingerprint
      3dc0fa7fd3f24c27a099cd47371d638c4e6ac45b071bcbdeb7f781ac115a91cd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:treprostinil
Content hash
69b9164487a54e6855c1ec2c62f078bb13729a4a2c4a9eec80dd893797684bcc